<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ACC</journal-id>
<journal-id journal-id-type="hwp">spacc</journal-id>
<journal-title>European Heart Journal: Acute Cardiovascular Care</journal-title>
<issn pub-type="ppub">2048-8726</issn>
<issn pub-type="epub">2048-8734</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2048872612441584</article-id>
<article-id pub-id-type="publisher-id">10.1177_2048872612441584</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Stent for Life Initiative: where are we standing and where are we going?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Widimsky</surname><given-names>Petr</given-names></name>
<xref ref-type="aff" rid="aff1-2048872612441584">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kristensen</surname><given-names>Steen Dalby</given-names></name>
<xref ref-type="aff" rid="aff2-2048872612441584">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2048872612441584"><label>1</label>Third Faculty of Medicine, Charles University Prague, Czech Republic</aff>
<aff id="aff2-2048872612441584"><label>2</label>Department of Cardiology, Aarhus University Hospital, Denmark</aff>
<author-notes>
<corresp id="corresp1-2048872612441584">Petr Widimsky, Cardiocenter, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34 Prague 10, Czech Republic. Email: <email>petr.widimsky@fnkv.cz</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>1</volume>
<issue>1</issue>
<fpage>48</fpage>
<lpage>49</lpage>
<permissions>
<copyright-statement>© The European Society of Cardiology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The first percutaneous coronary angioplasty (PTCA) for acute myocardial infarction was performed nearly 30 years ago in 1983.<sup><xref ref-type="bibr" rid="bibr1-2048872612441584">1</xref></sup> It took another 10 years before the first randomised trials published in 1993<sup><xref ref-type="bibr" rid="bibr2-2048872612441584">2</xref><xref ref-type="bibr" rid="bibr3-2048872612441584"/>–<xref ref-type="bibr" rid="bibr4-2048872612441584">4</xref></sup> had proven that primary PTCA is superior to thrombolysis in the treatment of acute myocardial infarction with ST-segment elevations (STEMI). Despite this evidence, primary angioplasty remained a rare reperfusion method used mostly for patients living near PTCA centres and presenting during working hours. Another 10 years elapsed before two larger multicentre randomised trials<sup><xref ref-type="bibr" rid="bibr5-2048872612441584">5</xref>,<xref ref-type="bibr" rid="bibr6-2048872612441584">6</xref></sup> showed that primary percutaneous coronary intervention (p-PCI) is also the best reperfusion strategy for distant patients who need to be transferred from a small hospital to a tertiary PCI centre during off-hours. The first guidelines defining p-PCI as the default reperfusion strategy were published by the Czech Society of Cardiology,<sup><xref ref-type="bibr" rid="bibr7-2048872612441584">7</xref></sup> followed by the European Society of Cardiology<sup><xref ref-type="bibr" rid="bibr8-2048872612441584">8</xref></sup> and the American College of Cardiology/American Heart Association.<sup><xref ref-type="bibr" rid="bibr9-2048872612441584">9</xref></sup> Thus, it took 20 years from the introduction of primary PTCA and 10 years from the original randomised trials evidence to define p-PCI as the default reperfusion strategy in official guidelines. This is incredibly slow compared to the fast transfer for a new drug, which is usually introduced to the guidelines within 1–2 years after a single large randomised trial has shown its benefit.</p>
<p>Simultaneously, evidence has been accumulating that shows the suboptimal implementation of emergent PCI for acute coronary syndromes.<sup><xref ref-type="bibr" rid="bibr10-2048872612441584">10</xref>,<xref ref-type="bibr" rid="bibr11-2048872612441584">11</xref></sup> On the other hand, the widespread use of PCI for chronic, stable coronary artery disease has had limited or no influence on mortality.<sup><xref ref-type="bibr" rid="bibr12-2048872612441584">12</xref></sup> Thus, PCI was used far more in symptomatic indications (without significant impact on mortality) than in prognostic indications (where it significantly improves patient outcomes). Thus, in 2008 the European Association for Percutaneous Cardiovascular Interventions (EAPCI) together with the Working Group on Acute Cardiac Care of the European Society of Cardiology (ESC) decided to support the widespread use of acute PCI, and launched the Stent for Life (SFL) Initiative on 13 September 2008.<sup><xref ref-type="bibr" rid="bibr13-2048872612441584">13</xref></sup> The first ‘diagnostic‘ step was to map the current situation for reperfusion treatment of acute myocardial infarction in Europe. The survey based on data from 30 countries collected in 2007 revealed extremely large differences in the implementation of reperfusion therapies between European countries.<sup><xref ref-type="bibr" rid="bibr14-2048872612441584">14</xref></sup></p>
<p>The second step – to actively change the reperfusion to primary pCI – immediately followed. The situation was quickly improving in many countries. In some of these, such as the United Kingdom and Slovakia, this was possible mainly through strategic and financial support from local governments, whereas in other countries (Bulgaria, Egypt, France, Greece, Italy, Portugal, Romania, Serbia, Spain and Turkey) it was facilitated by national SFL groups. Thus, now – less then 4 years after SFL initiation – primary PCI already is the dominant reperfusion therapy for STEMI in the majority of European countries.</p>
<p>Thus, the question now is: has the SFL Initiative already achieve its goals? Or are we just midway through with a lot of work still ahead? We have to wait for the detailed analysis of the second European SFL survey – carried out in 2011 with results available in late 2012. Irrespective of these results we strongly believe that the Stent for Life Initiative should not only continue, but probably even grow. After the ‘quantitative‘ phase (aimed at increasing primary angioplasty use for reperfusion therapy of STEMI) the SFL Initiative should focus on the ‘qualitative‘ parameters. Our aim should be to systematically record and shorten the time delays and to continue to facilitate the evolution of effective regional STEMI networks. We should open the STEMI networks for other critical situations in acute myocardial infarction (AMI), such as ST-depression myocardial infarction with ongoing ischaemia and AMI with acute heart failure, to facilitate implementation of new technologies and medications as evidence is collected to prove the benefit of these new strategies for patients with AMI. We believe that the Stent for Life Initiative is here to stay for the benefit of all European patients with AMI.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-2048872612441584">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>J</given-names></name>
<name><surname>Merx</surname><given-names>W</given-names></name>
<name><surname>Dorr</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Succesful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization and percutaneous transluminal coronary angioplasty</article-title>. <source>Am Heart J</source> <year>1982</year>; <volume>103</volume>: <fpage>132</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr2-2048872612441584">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zijlstra</surname><given-names>F</given-names></name>
<name><surname>de Boer</surname><given-names>MJ</given-names></name>
<name><surname>Hoorntje</surname><given-names>JCA</given-names></name>
<etal/>
</person-group>. <article-title>A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction</article-title>. <source>N Engl J Med</source> <year>1993</year>; <volume>328</volume>: <fpage>680</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr3-2048872612441584">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grines</surname><given-names>CL</given-names></name>
<name><surname>Browne</surname><given-names>KF</given-names></name>
<name><surname>Marco</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction</article-title>. <source>N Engl J Med</source> <year>1993</year>; <volume>328</volume>: <fpage>673</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr4-2048872612441584">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibbons</surname><given-names>RJ</given-names></name>
<name><surname>Holmes</surname><given-names>DR</given-names></name>
<name><surname>Reeder</surname><given-names>GS</given-names></name>
<etal/>
</person-group>. <article-title>Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction</article-title>. <source>N Engl J Med</source> <year>1993</year>; <volume>328</volume>: <fpage>685</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr5-2048872612441584">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Widimsky</surname><given-names>P</given-names></name>
<name><surname>Budesinsky</surname><given-names>T</given-names></name>
<name><surname>Vorac</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>‘PRAGUE’ Study Group Investigators. Long distance transport for primary angioplasty vs. immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial–PRAGUE-2</article-title>. <source>Eur Heart J</source> <year>2003</year>; <volume>24</volume>: <fpage>94</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr6-2048872612441584">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>HR</given-names></name>
<name><surname>Nielsen</surname><given-names>TT</given-names></name>
<name><surname>Rasmussen</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction</article-title>. <source>N Engl J Med</source> <year>2003</year>; <volume>349</volume>: <fpage>733</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr7-2048872612441584">
<label>7.</label>
<citation citation-type="journal">
<collab>The Czech Society of Cardiology guidelines for acute myocardial infarction with Q-waves/ST elevations/bundle branch block</collab>. <source>Cor Vasa</source> <year>2002</year>; <volume>44</volume>: <fpage>K123</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr8-2048872612441584">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van</surname><given-names>de</given-names></name>
<name><surname>Werf</surname><given-names>F</given-names></name>
<name><surname>Ardissino</surname><given-names>D</given-names></name>
<name><surname>Betriu</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology</article-title>. <source>Eur Heart J</source> <year>2003</year>; <volume>24</volume>: <fpage>28</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr9-2048872612441584">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antman</surname><given-names>EM</given-names></name>
<name><surname>Anbe</surname><given-names>DT</given-names></name>
<name><surname>Armstrong</surname><given-names>PW</given-names></name>
<etal/>
</person-group>. <article-title>American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction)</article-title>. <source>J Am Coll Cardiol</source> <year>2004</year>; <volume>44</volume>: <fpage>671</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr10-2048872612441584">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hasdai</surname><given-names>D</given-names></name>
<name><surname>Behar</surname><given-names>S</given-names></name>
<name><surname>Wallentin</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>A prospective survey of the characterisitics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey on Acute Coronary Syndromes (Euro Heart Survey ACS)</article-title>. <source>Eur Heart J</source> <year>2002</year>; <volume>23</volume>: <fpage>1190</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr11-2048872612441584">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rogers</surname><given-names>WJ</given-names></name>
<name><surname>Canto</surname><given-names>JG</given-names></name>
<name><surname>Barron</surname><given-names>HV</given-names></name>
<etal/>
</person-group>. <article-title>Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction</article-title>. <source>J Am Coll Cardiol</source> <year>2000</year>; <volume>35</volume>: <fpage>371</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr12-2048872612441584">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boden</surname><given-names>WE</given-names></name>
<name><surname>O’Rourke</surname><given-names>RA</given-names></name>
<name><surname>Teo</surname><given-names>KK</given-names></name>
<etal/>
</person-group>. <article-title>COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>356</volume>: <fpage>1503</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr13-2048872612441584">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Widimsky</surname><given-names>P</given-names></name>
<name><surname>Fajadet</surname><given-names>J</given-names></name>
<name><surname>Danchin</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>“Stent 4 Life” targeting PCI at all who will benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac Care</article-title>. <source>EuroIntervention</source> <year>2009</year>; <volume>4</volume>: <volume>555</volume>, <fpage>557</fpage>.</citation>
</ref>
<ref id="bibr14-2048872612441584">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Widimsky</surname><given-names>P</given-names></name>
<name><surname>Wijns</surname><given-names>W</given-names></name>
<name><surname>Fajadet</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>on behalf of the European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>943</fpage>–<lpage>57</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>